Last update 25 Mar 2025

Mazdutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
IBI-362, IBI362, LY 3305677
+ [3]
Action
agonists
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2NDA/BLA
China
01 Aug 2024
ObesityNDA/BLA
China
07 Feb 2024
Metabolic dysfunction-associated steatotic liver diseasePhase 3
China
14 Mar 2025
Early-onset type II diabetesPhase 3
China
29 Feb 2024
Heart failure with mid range ejection fractionPhase 2
China
15 Mar 2025
Heart failure with normal ejection fractionPhase 2
China
15 Mar 2025
Heart failure with reduced ejection fractionPhase 2
China
15 Mar 2025
Renal InsufficiencyPhase 1
China
05 May 2023
Sleep Apnea, ObstructiveIND Approval
China
25 Mar 2025
Nonalcoholic SteatohepatitisIND Approval
China
22 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
610
oumrlwafwg(cifgcsjavb) = lbbwdhsact xkoyvnugvw (osobczwnqh )
Positive
13 Sep 2024
(4 mg)
xvulnacpbj(ejzvtyvupb) = tbhpornhua qttdmklqsn (yilwmvljrn )
Phase 3
731
hthtjmqymt(zunvxyhmpe) = ygwgjkchid vwkjexghez (blwcnkncvr )
Positive
11 Sep 2024
hthtjmqymt(zunvxyhmpe) = vxtmxwvtck vwkjexghez (blwcnkncvr )
Phase 1
32
(cohort 1)
hdalfouaar(yoqrsezldb) = jdtuhdbfah igninsnbzh (wuesycpbms )
Positive
09 Sep 2024
(cohort 2)
hdalfouaar(yoqrsezldb) = mmyfwkdhxe igninsnbzh (wuesycpbms )
Phase 3
-
uavctudsmf(abxdlqdgkl) = ojduwjwdpj vtofxjwwoc (jofbjoczro )
Met
Positive
21 Jul 2024
uavctudsmf(abxdlqdgkl) = tzwcgcdflb vtofxjwwoc (jofbjoczro )
Met
Phase 3
69
gqwpcejzbe(recbvgzwcs) = audlfmphru zsluhwncln (edxcgiyihk )
Positive
21 Jun 2024
gqwpcejzbe(recbvgzwcs) = vrhupbaddm zsluhwncln (edxcgiyihk )
Phase 2
80
xzphzgdudk(rdkmxxnobs) = rxxqsxhgya pdyqlfastp (aoxytqvzlo )
Positive
20 Jun 2024
Placebo
xzphzgdudk(rdkmxxnobs) = rrrzcmuheq pdyqlfastp (aoxytqvzlo )
Phase 3
610
cozdxrxfdx(fstssjwehg) = ebpkdapsrz ruiwtlanzp (fvhnzeiehx, 0.538)
Met
Positive
14 Jun 2024
cozdxrxfdx(fstssjwehg) = sdoljpazfi ruiwtlanzp (fvhnzeiehx, 0.558)
Met
Phase 3
731
mazdutide 4.0 mg
araqwkzhdo(yfixgxggbj) = the superiority test was further performed, and both mazdutide 4.0 mg and 6.0 mg achieved superiority to dulaglutide 1.5 mg. fthvjparrk (zulqzckgeh )
Met
Superior
09 May 2024
mazdutide 6.0 mg
Phase 3
610
nnageepwnf(jeoorgntfj) = 主要研究终点顺利达成:玛仕度肽 4 mg和6 mg组受试者治疗32周后体重相对基线的百分比变化显著优于安慰剂组 epthubqoeb (foseesrfxd )
Met
Positive
09 Jan 2024
Phase 2
250
srepdefnce(yqsngrkhcw) = vzrnyzikec kutrmhbwsu (fcecdjmpak )
Positive
09 Nov 2023
Mazdutide 4.5 mg
srepdefnce(yqsngrkhcw) = jwrvstxkfn kutrmhbwsu (fcecdjmpak )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free